Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Stephens

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Lancet (London, England)|September 9, 2016
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trialPaula Mulvenna, Matthew Nankivell, Rachael Barton, et al.
BMC Medicine|July 5, 2023
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE studyOlga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
European Heart Journal|March 23, 2017
Improving public health by improving clinical trial guidelines and their applicationMartin J Landray, Jeroen J Bax, Laurence Alliot, et al.
Research Involvement and Engagement|July 19, 2022
Standardised data on initiatives-STARDIT: Beta versionJack S Nunn, Thomas Shafee, Steven Chang, et al.
Current Drug Abuse Reviews|August 18, 2010
The alcohol hangover research group consensus statement on best practice in alcohol hangover researchJoris C Verster, Richard Stephens, Renske Penning, et al.
Drug Discovery Today|April 18, 2026
Decentralised clinical trials of investigational medicinal productsAbdel Douiri, Mohammad Alhnan, Muhammad Rizwan Asghar, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.
Lancet (London, England)|September 9, 2016
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trialPaula Mulvenna, Matthew Nankivell, Rachael Barton, et al.
BMC Medicine|July 5, 2023
Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE studyOlga Solovyeva, Munyaradzi Dimairo, Christopher J Weir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
European Heart Journal|March 23, 2017
Improving public health by improving clinical trial guidelines and their applicationMartin J Landray, Jeroen J Bax, Laurence Alliot, et al.
Research Involvement and Engagement|July 19, 2022
Standardised data on initiatives-STARDIT: Beta versionJack S Nunn, Thomas Shafee, Steven Chang, et al.
Current Drug Abuse Reviews|August 18, 2010
The alcohol hangover research group consensus statement on best practice in alcohol hangover researchJoris C Verster, Richard Stephens, Renske Penning, et al.
Drug Discovery Today|April 18, 2026
Decentralised clinical trials of investigational medicinal productsAbdel Douiri, Mohammad Alhnan, Muhammad Rizwan Asghar, et al.
JAMA|February 8, 2018
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO ExtensionMelanie Calvert, Derek Kyte, Rebecca Mercieca-Bebber, et al.
Pageof 13